Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-700
Closed -$644K 83
2026
Q1
$644K Buy
+700
New +$710K 0.03% 77
2025
Q4
Sell
-200
Closed -$153K 158
2025
Q3
$153K Buy
+200
New +$149K 0.02% 90
2023
Q1
Sell
-500
Closed -$183K 94
2022
Q4
$183K Sell
500
-14,400
-97% -$5.11M 0.02% 117
2022
Q3
$4.82M Buy
14,900
+5,600
+60% +$1.77M 0.39% 38
2022
Q2
$3.02M Sell
9,300
-15,400
-62% -$4.62M 0.22% 59
2022
Q1
$7.08M Buy
+24,700
New +$6.36M 0.27% 71
2021
Q4
Sell
-5,900
Closed -$1.36M 168
2021
Q3
$1.36M Buy
5,900
+3,200
+119% +$790K 0.09% 174
2021
Q2
$621K Buy
2,700
+1,200
+80% +$241K 0.06% 156
2021
Q1
$280K Buy
1,500
+700
+88% +$137K 0.03% 98
2020
Q4
$136K Buy
+800
New +$119K 0.01% 85

Other funds holding LLY

QVR's LLY Position: Q1 2026 in Review

QVR sold out of Eli Lilly (LLY) in Q1 2026, closing a stake of 7,177 shares — an estimated $7.28M sold.

QVR first reported a position in LLY in Q2 2021 and held it in 6 quarters. The position peaked at $7.71M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • QVR reported no remaining Eli Lilly position as of Q1 2026 after selling out during the quarter.
  • QVR sold 7,177 Eli Lilly shares in Q1 2026, an estimated $7.28M.
  • QVR first reported a position in Eli Lilly in Q2 2021 and held it in 6 quarters.
  • QVR's Eli Lilly position peaked at $7.71M in Q4 2025.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on QVR's 13F filing for Q1 2026, filed 15 Apr 2026.